ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neurological Biomarkers
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1656974
Untargeted Metabolomic Profiling in Acute Ischemic Stroke Patients with Cerebral Microbleeds
Provisionally accepted
- 1Affiliated Hospital, Ningbo University, Ningbo, China
- 2Ningbo Yinzhou District Third Hospital, Ningbo, China
- 3The First Affiliated Hospital of Ningbo University, Ningbo, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Acute ischemic stroke (AIS) is a common cerebrovascular condition. Cerebral microbleeds (CMBs) are frequently observed in AIS patients and are closely associated with poor prognosis and potential therapeutic implications. Understanding the distinct metabolic profiles in AIS patients with CMBs is critical for uncovering the underlying pathophysiological mechanisms and identifying novel biomarkers. Methods: An untargeted metabolomics approach using liquid chromatography–mass spectrometry (LC-MS) was employed to compare the metabolic profiles of 30 AIS patients with CMBs (CMB group) and 30 AIS patients without CMBs (NCMB group). Raw MS data were processed using MS-DIAL and metabolites were identified by comparison with public and in-house databases. Both univariate and multivariate analyses (PCA, OPLS-DA) were used to identify differential metabolites, followed by KEGG pathway enrichment analysis. Results: The LC-MS platform demonstrated robust stability and high data quality. Multivariate statistical modeling successfully distinguished between the two groups, revealing distinct metabolic phenotypes. A total of 156 significantly altered metabolites were identified, including 103 upregulated and 53 downregulated metabolites. Pathway analysis revealed significant perturbations in lipid metabolism, amino acid metabolism, and energy metabolism. Conclusion: This study identified unique metabolic signatures in AIS patients with CMBs. The metabolites such as N-ethylglycine, aspartyl-glutamate, and oleamide were significantly elevated, while metabolites like PC(16:0/18:1) and PC(18:0/20:4) were significantly reduced., and other metabolites implicated disruptions in energy and lipid metabolism. These findings suggest potential biomarker candidates for diagnosis, prognosis, and therapeutic intervention in this high-risk population.
Keywords: Stroke, cerebral microbleeds, Metabolomics, Cerebral small vessel disease, mechanisms
Received: 30 Jun 2025; Accepted: 25 Aug 2025.
Copyright: © 2025 Zhou, Sun, Li and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Qing Han, The First Affiliated Hospital of Ningbo University, Ningbo, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.